-1.21% for AstraZeneca stock — sellers dominate despite EMA validation for key treatment

Traders Union
All News
Financial News
AstraZeneca slides 1.21% today

Highlights

The European Medicines Agency validated the application for DATROWAY, developed with Daiichi Sankyo, following strong phase 3 results in metastatic triple negative breast cancer.
Compugen monetized future royalties from rilvegostomig through a revised AstraZeneca partnership, receiving an immediate $65 million payment.
AstraZeneca Pharma India secured approval to import, sell, and distribute Datopotamab Deruxtecan, with minor institutional shareholding changes also recorded.

New cancer drug approvals and strategic partnerships reshape sentiment

AstraZeneca's recent news flow highlights key corporate developments, notably the European Medicines Agency's validation of the application for DATROWAY, developed with Daiichi Sankyo, after strong phase 3 results in metastatic triple negative breast cancer. Compugen has revised its partnership with AstraZeneca, monetizing future royalties from rilvegostomig for an immediate $65 million payment. AstraZeneca Pharma India was also granted approval to import, sell, and distribute the new breast cancer treatment Datopotamab Deruxtecan. Minor institutional shareholding changes were recorded during this period.

Diverging momentum and oscillators as daily trading pressures downside

Momentum indicators remain mixed for AZN on the daily chart. The MACD is giving a strong buy signal and the ADX confirms ongoing trend strength, but Stoch RSI is in oversold territory while the RSI sits at 52.93, suggesting possible short-term exhaustion. The CCI indicator leans bearish, and BBP indicates overbought conditions, pointing to increased intraday selling momentum. Trading has been pressured to the downside, with price action at the lower end of today’s GBX 13,430.00 – 13,534.00 range amid moderate volatility; persistent post-open declines reflect this divergence between momentum and oscillators, creating potential for a short-term bounce.

Consolidation likely as upside signals outweigh limited short-term risks

Over the coming five days, AZN is expected to consolidate within the GBX 13,200.00 to GBX 13,900.00 range, reflecting a typical volatility band relative to current levels. Technical signals show a high probability (over 80%) of upward movement, with strong buy signals on the weekly MACD, RSI, and moving averages. Downside risk appears limited (below 20%), and the baseline scenario anticipates sideways trading within this corridor. If renewed buying pressure pushes the price above the Ichimoku Kijun, a move toward GBX 13,900.00 is likely, while increased selling may see support near GBX 13,200.00 tested.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca as maintaining technical resilience above long-term averages, but notes caution due to current weakness under the MA-20 and mixed momentum signals on the daily chart. He points out that positive industry news and strong weekly buy signals suggest limited downside, yet intraday pressures and conflicting indicators warrant a defensive stance. Kharitonov believes the probability leans toward sideways or modest upward movement within the GBX 13,200.00 to GBX 13,900.00 range. "I remain cautious: unless the price breaks above the Ichimoku Kijun at GBX 13,762.00, upside conviction is limited and I prefer to see confirmation before getting involved."

Last time, analysts noted AstraZeneca PLC is exhibiting near-term seller pressure as it trades below its 20-day moving average, while remaining above its 50- and 200-day averages to maintain a medium- to long-term bullish bias. Momentum signals remain broadly positive with ongoing bullish MACD and ADX, though overbought oscillators and mixed readings from RSI and CCI highlight emerging exhaustion as the stock consolidates below defined resistance.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.